This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in this journal  Topic Collections  • Aging/ Geriatrics  • Cardiovascular System  • Statistics and Research Methods  • Prognosis/ Outcomes  • Drug Therapy, Other  • Congestive Heart Failure/ Cardiomyopathy  • Alert me on articles by topic  Social Bookmarking   What's this?

Brian L. Strom, MD, MPH

Arch Intern Med. 2008;168(22):2428-2431.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The US Food and Drug Administration approves most drugs based on rigorous randomized clinical trials showing that the drug is "efficacious," which is operationally defined as statistically superior to placebo. However, a number of critically important knowledge gaps exist long after a drug is approved. For example, many drugs are approved based on studies of a surrogate end point, which is a biological marker or event observable earlier than the clinical end points that are actually of primary interest. For instance, antihypertensive drugs are usually approved on the basis of their ability to reduce blood pressure rather than on their ability to reduce the risk of the clinically important consequences of high blood pressure such as stroke. Unfortunately, reliance on surrogate end points can sometimes produce disastrous results. Encainide hydrochloride and flecainide acetate, 2 antiarrhythmic drugs approved in the early 1980s based on their ability . . . [Full Text of this Article]

AUTHOR INFORMATION


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

Comparative Effectiveness of Different β-Adrenergic Antagonists on Mortality Among Adults With Heart Failure in Clinical Practice
Alan S. Go, Jingrong Yang, Jerry H. Gurwitz, John Hsu, Kimberly Lane, and Richard Platt
Arch Intern Med. 2008;168(22):2415-2421.
ABSTRACT | FULL TEXT  

Comparative Effectiveness of β-Blockers in Elderly Patients With Heart Failure
Judith M. Kramer, Lesley H. Curtis, Carla S. Dupree, David Pelter, Adrian Hernandez, Mark Massing, and Kevin J. Anstrom
Arch Intern Med. 2008;168(22):2422-2428.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Correction: Which Beta-Blocker is Best for Patients with Heart Failure?
Journal Watch Cardiology 2009;2009:3-3.
FULL TEXT